Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1991-5-1
|
pubmed:language |
ger
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0017-6001
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
30 Suppl 1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
53-5
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:2127766-Combined Modality Therapy,
pubmed-meshheading:2127766-Drug Evaluation,
pubmed-meshheading:2127766-Female,
pubmed-meshheading:2127766-Humans,
pubmed-meshheading:2127766-Interferon-gamma,
pubmed-meshheading:2127766-Ovarian Neoplasms,
pubmed-meshheading:2127766-Picibanil,
pubmed-meshheading:2127766-Recombinant Proteins
|
pubmed:year |
1990
|
pubmed:articleTitle |
[Therapy with biomodulators in ovarian cancer].
|
pubmed:affiliation |
II. Universitäts-Frauenklinik Wien.
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|